SLC22A2 and ovarian cancer: CIM is a potent inhibitor of OCT2, and in vitro investigations showed that it did not alter the uptake or cytotoxicity of cisplatin in an ovarian cancer cell line (IGROV-1) expressing high levels of OCT2.